

Safer, targeted anti-coagulants to minimise risk of bleeding and stroke

The Invention

One of the major risks associated with surgery is stroke.

In order to minimise the risk of stroke, patients are normally given anti-coagulants like heparin which prevent the blood from forming dangerous clots that could dislodge and block blood flow through arteries, potentially resulting in a pulmonary embolus or stroke (when the clots get stuck to the lungs or brain, respectively).

Our hospital-based researchers have developed specific antibodies that attach to an existing anti-coagulant drug to optimise its action, yet minimise toxicity and its most common undesired side-effect, increased bleeding.

Key Benefits

- Antibodies have been designed and conjugated to a well-known, anticoagulant drug (Lepirudin)
- With many years of clinical data Lepirudin is now off patent, opening the doors for much cheaper generic drugs.
- The specifically designed antibodies only target sites where blood is beginning to clot
- Increased specificity with decreased amount of the drug required (which can sometimes be toxic)
- Improved drug efficacy.



The Opportunity

We are seeking potential research collaborators and pharmaceutical industry partners to further develop the invention.

Available under licence for FREE

The invention is available for FREE as an Easy Access IP License to companies and individuals.



For more information contact:

Dr Alfredo Martinez-Coll

Senior Business Development Manager

NewSouth Innovations Pty Ltd

Ref 12_2743

T: +61 2 9385 4679 | M: +61 404 014 686

E: a.martinez-coll@nsinnovations.com.au